NCT04229290 - Second-line Switch to Dolutegravir Study | Biotech Hunter

Enrollment

795

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

September 16, 2021

Study Completion Date

September 16, 2021

Conditions

HIV-1-infection

Interventions

DRUG

Dolutegravir

Switch of virally suppressed participants to Dolutegravir

Trial Locations (4)

Kiambu Level 5 Hospital, Kiambu

Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu

Kenyatta National Hospital, Nairobi

Thika Level 5 Hospital, Thika